Literature DB >> 10155288

How much faith can we have in pharmacoeconomic analyses?

H T Hatoum, S X Kong.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 10155288     DOI： 10.2165/00019053-199406060-00012

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

1.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 2.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

3.  Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol.

Authors:  J D Bentkover; A M Baker; H Kaplan
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

4.  Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs.

Authors:  A L Hillman; B S Bloom
Journal:  Arch Intern Med       Date:  1989-09

5.  A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.

Authors:  S H Roth; E A Tindall; A K Jain; F G McMahon; P A April; B I Bockow; S B Cohen; R M Fleischmann
Journal:  Arch Intern Med       Date:  1993-11-22
  5 in total
  1 in total

1.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.